Open label trial demonstrates safety and effective serum levels of nirsevimab in Japanese infants, indicating potential for RSV prevention.
In Japanese infants aged ≤12 months at risk for severe RSV-associated lower respiratory tract infections who received two doses of nirsevimab 5-6 months apart, no safety concerns or anti-drug antibodies occurred. Nirsevimab serum concentrations were consistent with those previously demonstrated to be efficacious in healthy preterm and term infants.
No takes yet. Share an insight, caveat, or question.
Mori et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: